Matthew Movsesian
Overview
Explore the profile of Matthew Movsesian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sucharov C, Nakano S, Slavov D, Schwisow J, Rodriguez E, Nunley K, et al.
J Am Coll Cardiol
. 2019 Mar;
73(10):1173-1184.
PMID: 30871701
Background: The phosphodiesterase 3A (PDE3A) gene encodes a PDE that regulates cardiac myocyte cyclic adenosine monophosphate (cAMP) levels and myocardial contractile function. PDE3 inhibitors (PDE3i) are used for short-term treatment...
2.
Humphrey J, Movsesian M, Am Ende C, Becker S, Chappie T, Jenkinson S, et al.
J Med Chem
. 2018 May;
61(10):4635-4640.
PMID: 29718668
We disclose the discovery and X-ray cocrystal data of potent, selective quinazoline inhibitors of PDE1. Inhibitor ( S)-3 readily attains free plasma concentrations above PDE1 IC values and has restricted...
3.
Movsesian M, Ahmad F, Hirsch E
J Cardiovasc Dev Dis
. 2018 Feb;
5(1).
PMID: 29415428
Isoforms in the PDE3 family of cyclic nucleotide phosphodiesterases have important roles in cyclic nucleotide-mediated signalling in cardiac myocytes. These enzymes are targeted by inhibitors used to increase contractility in...
4.
5.
Movsesian M
Pharmacol Ther
. 2016 Apr;
163:74-81.
PMID: 27108947
Inhibitors of PDE3, a family of dual-specificity cyclic nucleotide phosphodiesterases, are used clinically to increase cardiac contractility by raising intracellular cAMP content in cardiac myocytes and to reduce vascular resistance...
6.
Zoccarato A, Surdo N, Aronsen J, Fields L, Mancuso L, Dodoni G, et al.
Circ Res
. 2015 Aug;
117(8):707-19.
PMID: 26243800
Rationale: Chronic elevation of 3'-5'-cyclic adenosine monophosphate (cAMP) levels has been associated with cardiac remodeling and cardiac hypertrophy. However, enhancement of particular aspects of cAMP/protein kinase A signaling seems to...
7.
Movsesian M
Curr Opin Cardiol
. 2015 Mar;
30(3):285-91.
PMID: 25807221
Purpose Of Review: The most extensively studied inotropic agents in patients with heart failure are phosphodiesterase (PDE) 3 inhibitors, which increase contractility by raising intracellular cyclic adenosine monophosphate content. In...
8.
Ahmad F, Shen W, Vandeput F, Szabo-Fresnais N, Krall J, Degerman E, et al.
J Biol Chem
. 2015 Jan;
290(11):6763-76.
PMID: 25593322
Cyclic nucleotide phosphodiesterase 3A (PDE3) regulates cAMP-mediated signaling in the heart, and PDE3 inhibitors augment contractility in patients with heart failure. Studies in mice showed that PDE3A, not PDE3B, is...
9.
Nakano S, Miyamoto S, Movsesian M, Nelson P, Stauffer B, Sucharov C
Circ Heart Fail
. 2014 Oct;
8(1):57-63.
PMID: 25278000
Background: Despite the application of proven adult heart failure therapies to children with idiopathic dilated cardiomyopathy (IDC), prognosis remains poor. Clinical experience with phosphodiesterase 3 inhibitors (PDE3i) in pediatric patients...
10.
Drakos S, Wever-Pinzon O, Selzman C, Gilbert E, Alharethi R, Reid B, et al.
J Am Coll Cardiol
. 2013 Mar;
61(19):1985-94.
PMID: 23500219
Objectives: This study sought to prospectively investigate the longitudinal effects of continuous-flow left ventricular assist device (LVAD) unloading on myocardial structure and systolic and diastolic function. Background: The magnitude, timeline,...